Holen Sie sich die Stockscreener-App
14.75
1.30%
0.19
Schlusskurs vom Vortag:
$14.56
Offen:
$14.58
24-Stunden-Volumen:
343.71K
Relative Volume:
0.17
Marktkapitalisierung:
$1.71B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-804.34M
KGV:
-1.5675
EPS:
-9.41
Netto-Cashflow:
$-531.06M
1W Leistung:
-5.99%
1M Leistung:
-7.93%
6M Leistung:
-59.03%
1J Leistung:
-54.99%
1-Tages-Spanne:
$14.32
$14.91
1-Wochen-Bereich:
$14.32
$16.19
52-Wochen-Spanne:
$14.32
$55.70
Biohaven Ltd Stock (BHVN) Company Profile
Firmenname
Biohaven Ltd
Sektor
Branche
Telefon
203-404-0410
Adresse
215 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie BHVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
14.75 | 1.71B | 0 | -804.34M | -531.06M | -9.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.43 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.87 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.07 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.91 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
256.62 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-09-16 | Eingeleitet | Jefferies | Buy |
| 2024-09-04 | Eingeleitet | Bernstein | Outperform |
| 2024-07-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2023-12-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-01-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-04 | Eingeleitet | JP Morgan | Overweight |
| 2022-12-02 | Eingeleitet | BTIG Research | Buy |
| 2022-10-26 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-05-11 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Herabstufung | UBS | Buy → Neutral |
| 2021-08-03 | Bestätigt | Canaccord Genuity | Buy |
| 2021-03-11 | Eingeleitet | UBS | Buy |
| 2020-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-17 | Eingeleitet | Cowen | Outperform |
| 2020-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Outperform |
| 2019-06-25 | Bestätigt | Canaccord Genuity | Buy |
| 2019-05-06 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Bestätigt | Needham | Buy |
| 2018-07-03 | Bestätigt | Needham | Buy |
| 2018-07-02 | Bestätigt | Needham | Buy |
| 2018-04-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Bestätigt | Canaccord Genuity | Buy |
| 2017-12-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-03 | Bestätigt | Needham | Buy |
Alle ansehen
Biohaven Ltd Aktie (BHVN) Neueste Nachrichten
Biohaven (BHVN) Target Price Lowered by JP Morgan Analyst | BHVN Stock News - GuruFocus
Biohaven (BHVN) Price Target Lowered by JPMorgan to $55 | BHVN Stock News - GuruFocus
Biohaven price target lowered to $55 from $68 at JPMorgan - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. ... - Bluefield Daily Telegraph
Biohaven Insiders Added US$6.28m Of Stock To Their Holdings - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd.BHVN - PR Newswire
Investigation Underway: Biohaven Ltd. (BHVN)Contact Levi & Korsinsky Over Securities Law Violations - ACCESS Newswire
New Haven-based bioscience firms Bexorg, Biohaven agree to collaborate - Hartford Business Journal
BHVN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Biohaven Ltd. - ACCESS Newswire
Biohaven (BHVN) Teams Up with Bexorg for CNS Disorder Research C - GuruFocus
Kalkine : Biohaven Ltd Shift Amid Sector Moves and Earnings Per Share Focus - Kalkine Media
Biohaven, Bexorg Collaborate to Develop CNS Therapies - marketscreener.com
Biohaven (BHVN) Teams Up with Bexorg for CNS Disorder Research Collaboration | BHVN Stock News - GuruFocus
Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development - The Manila Times
Bexorg announces multi-program research collaboration with Biohaven - TipRanks
Bexorg Announces Research Collaboration with Biohaven - GlobeNewswire
Biohaven Ltd. (NYSE:BHVN) Shares Purchased by Parallel Advisors LLC - Defense World
Levi & Korsinsky Investigates Possible Securities Fraud by Biohaven Ltd. (BHVN) - ACCESS Newswire
Fraud Investigation: Levi & Korsinsky Investigates Biohaven Ltd. (BHVN) on Behalf of Shareholders - ACCESS Newswire
Levi & Korsinsky Investigating Whether Biohaven Ltd. (BHVN) Misled InvestorsSecurities Law Violations Possible - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - GlobeNewswire Inc.
Ongoing Biohaven Ltd. (BHVN) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
Biohaven Ltd. Highlights Strategic Focus in Investor Presentation - MSN
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Biohaven Ltd. (BHVN) - ACCESS Newswire
Sector Update: Health Care - marketscreener.com
Biohaven Shares Rise on Drug Pipeline Update With Two Near-Market Candidates - marketscreener.com
Shareholders Alert: Investigation Into Biohaven Ltd. (BHVN)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Biohaven Ltd.: Promising Pipeline and Undervaluation Justify Buy Rating - TipRanks
Jim Cramer on Biohaven Ltd. (BHVN): “I Think That This is a Buy” - Insider Monkey
Jim Cramer’s Thoughts on These 10 Stocks - Insider Monkey
Biohaven Lands Major $600 Million Deal With Oberland Capital - Finimize
How To Trade (BHVN) - news.stocktradersdaily.com
Biohaven Ltd. Receives Buy Rating Amidst Promising Developments and Strategic Advancements - TipRanks
Biohaven stock hits 52-week low at $14.36 amid market challenges By Investing.com - Investing.com South Africa
Morgan Stanley maintains Biohaven stock with $63 target - Investing.com Australia
BHVN Investor Notice: Levi & Korsinsky Investigates Biohaven Ltd. for Securities Law Violations - ACCESS Newswire
Biohaven stock hits 52-week low at $14.36 amid market challenges - Investing.com Nigeria
H.C. Wainwright maintains Buy on Biohaven stock, $54 price target - Investing.com Australia
H.C. Wainwright maintains Buy on Biohaven stock, $54 price target By Investing.com - Investing.com India
Biohaven Ltd. Receives Buy Rating from Douglas Tsao Amid Promising R&D Advancements and Strategic Developments - TipRanks
Investors in Biohaven Ltd. (BHVN) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Cowen reiterates Buy on Biohaven stock, maintains $75 target By Investing.com - Investing.com South Africa
Biohaven Ltd. Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor - marketscreener.com
Cowen reiterates Buy on Biohaven stock, maintains $75 target - Investing.com
Biohaven (BHVN) Commences Innovative Phase 2/3 Parkinson's Drug - GuruFocus
Biohaven initiates global Phase 2/3 study of BHV-8000 - TipRanks
Biohaven (BHVN) Commences Innovative Phase 2/3 Parkinson's Drug Trial | BHVN Stock News - GuruFocus
TD Cowen on Biohaven Pharmaceutical Holding (BHVN): 'This Pipeline Is Impressive', 'Buy BHVN' - StreetInsider
Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor - PR Newswire
Biohaven’s BHV-1510 shows promise in early cancer trial By Investing.com - Investing.com South Africa
Biohaven’s BHV-1400 shows promise in IgA nephropathy treatment By Investing.com - Investing.com South Africa
Finanzdaten der Biohaven Ltd-Aktie (BHVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.59%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):